Johnson & Johnson plans to separate orthopaedics unit DePuy Synthes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business
October 14, 2025 6:21 AM EDTStrengthens focus of Johnson & Johnson as an innovation powerhouse and accelerates the portfolio shift of its MedTech Segment to higher-growth and higher-margin markets
Standalone orthopaedics business would operate as DePuy Synthes and be the largest, most comprehensive orthopaedics-focused company in the world
Namal Nawana appointed to serve as Worldwide President of DePuy Synthes
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (the Company) (NYSE: JNJ) today announced the Companys intent to separate its Orthopaedics business to enhance... More
